163 related articles for article (PubMed ID: 37499740)
21. Calbindin S100A16 Promotes Renal Cell Carcinoma Progression and Angiogenesis via the VEGF/VEGFR2 Signaling Pathway.
Wang N; Wang R; Tang J; Gao J; Fang Z; Zhang M; Shen X; Lu L; Chen Y
Contrast Media Mol Imaging; 2022; 2022():5602011. PubMed ID: 36176934
[TBL] [Abstract][Full Text] [Related]
22. Organ-specific endoglin (CD105) expression in the angiogenesis of human cancers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Pathol Int; 2006 Dec; 56(12):717-23. PubMed ID: 17096728
[TBL] [Abstract][Full Text] [Related]
23. Perfusion of 99Tcm-labeled CD105 Mab into kidneys from patients with renal carcinoma suggests that CD105 is a promising vascular target.
Costello B; Li C; Duff S; Butterworth D; Khan A; Perkins M; Owens S; Al-Mowallad AF; O'Dwyer S; Kumar S
Int J Cancer; 2004 Apr; 109(3):436-41. PubMed ID: 14961584
[TBL] [Abstract][Full Text] [Related]
24. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
25. Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.
Fiedorowicz M; Khan MI; Strzemecki D; Orzeł J; Wełniak-Kamińska M; Sobiborowicz A; Wieteska M; Rogulski Z; Cheda L; Wargocka-Matuszewska W; Kilian K; Szczylik C; Czarnecka AM
Sci Rep; 2020 Mar; 10(1):5379. PubMed ID: 32214151
[TBL] [Abstract][Full Text] [Related]
26. Description of 2 angiogenic phenotypes in clear cell renal cell carcinoma.
Edeline J; Mottier S; Vigneau C; Jouan F; Perrin C; Zerrouki S; Fergelot P; Patard JJ; Rioux-Leclercq N
Hum Pathol; 2012 Nov; 43(11):1982-90. PubMed ID: 22626276
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical evaluation of the microvascular density through the expression of TGF-beta (CD 105/endoglin) and CD 34 receptors and expression of the vascular endothelial growth factor (VEGF) in oligodendrogliomas.
Netto GC; Bleil CB; Hilbig A; Coutinho LM
Neuropathology; 2008 Feb; 28(1):17-23. PubMed ID: 18181830
[TBL] [Abstract][Full Text] [Related]
28. Listeria-based immunotherapy directed against CD105 exerts anti-angiogenic and anti-tumor efficacy in renal cell carcinoma.
Oladejo M; Nguyen HM; Silwal A; Reese B; Paulishak W; Markiewski MM; Wood LM
Front Immunol; 2022; 13():1038807. PubMed ID: 36439126
[TBL] [Abstract][Full Text] [Related]
29. Abnormal expression of Endoglin and its receptor complex (TGF-β1 and TGF-β receptor II) as early angiogenic switch indicator in premalignant lesions of the colon mucosa.
Bellone G; Gramigni C; Vizio B; Mauri FA; Prati A; Solerio D; Dughera L; Ruffini E; Gasparri G; Camandona M
Int J Oncol; 2010 Nov; 37(5):1153-65. PubMed ID: 20878063
[TBL] [Abstract][Full Text] [Related]
30. RUNX3 suppresses migration, invasion and angiogenesis of human renal cell carcinoma.
Chen F; Bai J; Li W; Mei P; Liu H; Li L; Pan Z; Wu Y; Zheng J
PLoS One; 2013; 8(2):e56241. PubMed ID: 23457532
[TBL] [Abstract][Full Text] [Related]
31. Circular RNAs in renal cell carcinoma: implications for tumorigenesis, diagnosis, and therapy.
Wang Y; Zhang Y; Wang P; Fu X; Lin W
Mol Cancer; 2020 Oct; 19(1):149. PubMed ID: 33054773
[TBL] [Abstract][Full Text] [Related]
32. Endoglin (CD105): a review of its role in angiogenesis and tumor diagnosis, progression and therapy.
Nassiri F; Cusimano MD; Scheithauer BW; Rotondo F; Fazio A; Yousef GM; Syro LV; Kovacs K; Lloyd RV
Anticancer Res; 2011 Jun; 31(6):2283-90. PubMed ID: 21737653
[TBL] [Abstract][Full Text] [Related]
33. Endoglin (CD105) expression in angiogenesis of colon cancer: analysis using tissue microarrays and comparison with other endothelial markers.
Minhajat R; Mori D; Yamasaki F; Sugita Y; Satoh T; Tokunaga O
Virchows Arch; 2006 Feb; 448(2):127-34. PubMed ID: 16177881
[TBL] [Abstract][Full Text] [Related]
34. CD105 is a marker of tumour vasculature and a potential target for the treatment of head and neck squamous cell carcinoma.
Marioni G; D'Alessandro E; Giacomelli L; Staffieri A
J Oral Pathol Med; 2010 May; 39(5):361-7. PubMed ID: 20537053
[TBL] [Abstract][Full Text] [Related]
35. Modeling clear cell renal cell carcinoma and therapeutic implications.
Wolf MM; Kimryn Rathmell W; Beckermann KE
Oncogene; 2020 Apr; 39(17):3413-3426. PubMed ID: 32123314
[TBL] [Abstract][Full Text] [Related]
36. Differential expression and cytoplasm/membrane distribution of endoglin (CD105) in human tumour cell lines: Implications in the modulation of cell proliferation.
Postiglione L; Di Domenico G; Caraglia M; Marra M; Giuberti G; Del Vecchio L; Montagnani S; Macri M; Bruno EM; Abbruzzese A; Rossi G
Int J Oncol; 2005 May; 26(5):1193-201. PubMed ID: 15809709
[TBL] [Abstract][Full Text] [Related]
37. RNAi-mediated knockdown of vascular endothelial growth factor inhibits vascularization and tumor growth in renal cell carcinoma.
Gu M; Zhang K; Yao HJ; Zhou J; Peng YB; Xu MX; Wang Z
Int J Mol Med; 2015 Oct; 36(4):1063-72. PubMed ID: 26310563
[TBL] [Abstract][Full Text] [Related]
38. Endoglin (CD105) is a useful marker for evaluating microvessel density and predicting prognosis in esophageal squamous cell carcinoma.
Sakurai T; Okumura H; Matsumoto M; Uchikado Y; Owaki T; Kita Y; Setoyama T; Omoto I; Kijima Y; Ishigami S; Natsugoe S
Anticancer Res; 2014 Jul; 34(7):3431-8. PubMed ID: 24982351
[TBL] [Abstract][Full Text] [Related]
39. Endoglin: An accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies.
Fonsatti E; Del Vecchio L; Altomonte M; Sigalotti L; Nicotra MR; Coral S; Natali PG; Maio M
J Cell Physiol; 2001 Jul; 188(1):1-7. PubMed ID: 11382917
[TBL] [Abstract][Full Text] [Related]
40. Significance of CD 105 expression for tumour angiogenesis and prognosis in endometrial carcinomas.
Salvesen HB; Gulluoglu MG; Stefansson I; Akslen LA
APMIS; 2003 Nov; 111(11):1011-8. PubMed ID: 14629267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
